We Row For William: 157 Miles, One Nonstop Journey of Hope
On April 25, Joe Jackson and a dedicated crew of men including Jeremy Leever and Shaun Olson will embark on an extraordinary nonstop, overnight rowing journey covering 157 miles of the Rogue River to raise awareness and critical funds for his son, William Jackson, who is battling Duchenne muscular dystrophy (DMD).
Cure Rare Disease Awarded $5.69 Million CIRM Grant to Advance Gene Therapy for Spinocerebellar Ataxia Type 3
Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disorder with no current treatment.
Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer
Cure Rare Disease, a nonprofit biotechnology organization dedicated to advancing treatments for neglected rare and genetic diseases, is proud to announce Brittany Stineman as its new Chief Advancement Officer, effective January 2025.
Cure Rare Disease Expands Leadership Team and Board of Directors to Advance Mission
Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology organization, announces the addition of a Chief Advancement Officer to its leadership team and welcomes three new members to its board of directors. Markus Ward joins as Chief Advancement Officer, and Jeremy Sternberg, J.D., Klaus Veitinger, M.D., Ph.D., and Mike Williams join the Board of Directors.
Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board
Cure Rare Disease (CRD) - a nonprofit biotechnology company focused on developing treatments for ultra-rare diseases - announces the appointment of leading experts in the fields of gene therapy and neuromuscular disorders to its Scientific Advisory Board (SAB).
Cure Rare Disease Receives Muscular Dystrophy Association Grant
Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has been awarded an advocacy collaboration grant from the Muscular Dystrophy Association (MDA) to support research on novel reimbursement strategies for drugs developed for ultra-rare diseases, a key challenge for rare disease patients, including muscular dystrophy patients. As reimbursement decisions are dependent upon commercial approval through large clinical trials, potential therapies developed for the rare and ultra-rare diseases are unlikely to reach the threshold of criteria to support reimbursement.
Cure Rare Disease Acquires Laboratory Space for New Headquarters in Connecticut
Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.
Cure Rare Disease Receives FDA Approval to Administer First-in-Human CRISPR Therapeutic
Cure Rare Disease (CRD) - a Boston-based 501c3 nonprofit biotech - announces the approval from the U.S. Food and Drug Administration (FDA) to administer its very first therapeutic. The drug, named CRD-TMH-001, treats muscle promoter and exon 1 mutations on the dystrophin gene. With the IND approval process complete, the FDA has given the go-ahead, and dosing of the drug will occur imminently at UMass Chan Medical School.
